RESUMEN
Implementation of the seventh amendment to the EU Cosmetics Directive has driven much research into suitable in vitro alternative assays to support satisfactory risk assessments. One such assay is the reconstructed skin micronucleus (RSMN) assay. First reported in 2006, further development occurred and a standard protocol was published in 2011. To evaluate and optimise the assay at Covance Laboratories, we tested nine chemicals [4-nitrophenol (4-NP), cyclohexanone (CH), 2-ethyl-1,3-hexanediol (2-EHD), methyl methansulfonate (MMS), mitomycin C (MMC), ethyl nitrosourea (ENU), benzo[a]pyrene (BaP), cyclophosphamide (CPA) and vinblastine (VIN)] using the EpiDerm™ 3D skin model (MatTek Corporation®, IVLSL, Bratislava, Slovakia) and compared the data using the standard 48-h treatment regimen and also an emerging 72-h treatment protocol. The EpiDerm™ tissue has reportedly some metabolic capacity but data using 48-h treatments has provided mixed results. Our investigations demonstrate that the two chemicals requiring metabolic activation (BaP and CPA) were negative following the 48-h protocol but were clearly positive following 72-h treatment. Furthermore, Replication Index (RI) data showed higher RI values in vehicle control treatments (indicating increased cell division) across the treatment set following 72-h treatments. A general greater magnitude of micronucleus (MN) induction was also observed following test chemical treatment. These data suggest that the 72-h treatment protocol is more suitable as a standard approach for the detection of clastogenic, aneugenic and metabolically activated chemicals in the RSMN assay. For further assay optimisation, we compare the statistical power of scoring cells from duplicate or triplicate cultures per treatment concentration and provide recommendations.
Asunto(s)
Bioensayo/métodos , Daño del ADN , Laboratorios/normas , Pruebas de Micronúcleos/métodos , Pruebas de Micronúcleos/normas , Mutágenos/efectos adversos , Piel/patología , Humanos , Piel/efectos de los fármacos , Piel/metabolismoRESUMEN
The need to develop new tools and increase capacity to test pharmaceuticals and other chemicals for potential adverse impacts on human health and the environment is an active area of development. Much of this activity was sparked by two reports from the US National Research Council (NRC) of the National Academies of Sciences, Toxicity Testing in the Twenty-first Century: A Vision and a Strategy (2007) and Science and Decisions: Advancing Risk Assessment (2009), both of which advocated for "science-informed decision-making" in the field of human health risk assessment. The response to these challenges for a "paradigm shift" toward using new approach methodologies (NAMS) for safety assessment has resulted in an explosion of initiatives by numerous organizations, but, for the most part, these have been carried out independently and are not coordinated in any meaningful way. To help remedy this situation, a framework that presents a consistent set of criteria, universal across initiatives, to evaluate a NAM's fit-for-purpose was developed by a multi-stakeholder group of industry, academic, and regulatory experts. The goal of this framework is to support greater consistency across existing and future initiatives by providing a structure to collect relevant information to build confidence that will accelerate, facilitate and encourage development of new NAMs that can ultimately be used within the appropriate regulatory contexts. In addition, this framework provides a systematic approach to evaluate the currently-available NAMs and determine their suitability for potential regulatory application. This 3-step evaluation framework along with the demonstrated application with case studies, will help build confidence in the scientific understanding of these methods and their value for chemical assessment and regulatory decision-making.
Asunto(s)
Toma de Decisiones , Administración de la Seguridad , Humanos , Medición de Riesgo , Pruebas de ToxicidadRESUMEN
Quality control of cell cultures used in new in vitro toxicology assays is crucial to the provision of reliable, reproducible and accurate toxicity data on new drugs or constituents of new consumer products. This chapter explores the key scientific and ethical criteria that must be addressed at the earliest stages of developing toxicology assays based on human pluripotent stem cell (hPSC) lines. It also identifies key considerations for such assays to be acceptable for regulatory, laboratory safety and commercial purposes. Also addressed is the development of hPSC-based assays for the tissue and cell types of greatest interest in drug toxicology. The chapter draws on a range of expert opinion within the European Commission/Cosmetics Europe-funded alternative testing cluster SEURAT-1 and consensus from international groups delivering this guidance such as the International Stem Cell Banking Initiative. Accordingly, the chapter summarizes the most up-date best practices in the use and quality control of human Pluripotent Stem Cell lines in the development of in vitro toxicity assays from leading experts in the field.
Asunto(s)
Técnicas In Vitro/normas , Células Madre Pluripotentes/citología , Pruebas de Toxicidad/métodos , Diferenciación Celular , Proliferación Celular , Humanos , Control de CalidadRESUMEN
A number of influences including legislation, industry and academia have encouraged advances in computational toxicology and high-throughput testing to probe more broadly putative toxicity pathways. The aim of the 25th United Kingdom Mutagen Society (UKEMS) Industrial Genotoxicity Group Annual Meeting 2011 was to explore current and upcoming research tools that may provide new cancer risk estimation approaches and discuss the genotoxicity testing paradigm of the future. The meeting considered whether computer modelling, molecular biology systems and/or adverse outcome pathway approaches can provide more accurate toxicity predictions and whether high-content study data, pluripotent stem cells or new scientific disciplines, such as epigenetics and adductomics, could be integrated into the risk assessment process. With close collaboration between industry, academia and regulators next generation predictive models and high-content tools have the potential to transform genetic toxicology testing in the 21st century.
Asunto(s)
Pruebas de Mutagenicidad/métodos , Humanos , Pruebas de Mutagenicidad/normas , Pruebas de Mutagenicidad/tendencias , Toxicogenética/métodos , Toxicogenética/normas , Toxicogenética/tendenciasRESUMEN
ToxTracker is a mammalian cell reporter assay that predicts the genotoxic properties of compounds with high accuracy. By evaluating induction of various reporter genes that play a key role in relevant cellular pathways, it provides insight into chemical mode-of-action (MoA), thereby supporting discrimination of direct-acting genotoxicants and cytotoxic chemicals. A comprehensive interlaboratory validation trial was conducted, in which the principles outlined in OECD Guidance Document 34 were followed, with the primary objectives of establishing transferability and reproducibility of the assay and confirming the ability of ToxTracker to correctly classify genotoxic and non-genotoxic compounds. Reproducibility of the assay to predict genotoxic MoA was confirmed across participating laboratories and data were evaluated in terms of concordance with in vivo genotoxicity outcomes. Seven laboratories tested a total of 64 genotoxic and non-genotoxic chemicals that together cover a broad chemical space. The within-laboratory reproducibility (WLR) was up to 98% (73%-98% across participants) and the overall between-laboratory reproducibility (BLR) was 83%. This trial confirmed the accuracy of ToxTracker to predict in vivo genotoxicants with a sensitivity of 84.4% and a specificity of 91.2%. We concluded that ToxTracker is a robust in vitro assay for the accurate prediction of in vivo genotoxicity. Considering ToxTracker's robust standalone accuracy and that it can provide important information on the MoA of chemicals, it is seen as a valuable addition to the regulatory in vitro genotoxicity battery that may even have the potential to replace certain currently used in vitro battery assays.
Asunto(s)
Daño del ADN , Mamíferos , Animales , Humanos , Pruebas de Mutagenicidad , Reproducibilidad de los Resultados , Genes ReporterosRESUMEN
Error-corrected Next Generation Sequencing (ecNGS) is rapidly emerging as a valuable, highly sensitive and accurate method for detecting and characterizing mutations in any cell type, tissue or organism from which DNA can be isolated. Recent mutagenicity and carcinogenicity studies have used ecNGS to quantify drug-/chemical-induced mutations and mutational spectra associated with cancer risk. ecNGS has potential applications in genotoxicity assessment as a new readout for traditional models, for mutagenesis studies in 3D organotypic cultures, and for detecting off-target effects of gene editing tools. Additionally, early data suggest that ecNGS can measure clonal expansion of mutations as a mechanism-agnostic early marker of carcinogenic potential and can evaluate mutational load directly in human biomonitoring studies. In this review, we discuss promising applications, challenges, limitations, and key data initiatives needed to enable regulatory testing and adoption of ecNGS - including for advancing safety assessment, augmenting weight-of-evidence for mutagenicity and carcinogenicity mechanisms, identifying early biomarkers of cancer risk, and managing human health risk from chemical exposures.
Asunto(s)
Secuenciación de Nucleótidos de Alto Rendimiento , Mutágenos , Humanos , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Pruebas de Mutagenicidad , Mutación , Mutágenos/toxicidad , Carcinógenos/toxicidad , Carcinogénesis , Medición de RiesgoRESUMEN
With the publication of revised draft ICH guidelines (Draft ICH S2), there is scope and potential to establish a combined multi-end point in vivo assay to alleviate the need for multiple in vivo assays, thereby reducing time, cost and use of animals. Presented here are the results of an evaluation trial in which the bone-marrow and peripheral blood (via MicroFlow(®) flow cytometry) micronucleus tests (looking at potential chromosome breakage and whole chromosome loss) in developing erythrocytes or young reticulocytes were combined with the Comet assay (measuring DNA strand-breakage), in stomach, liver and blood lymphocytes. This allowed a variety of potential target tissues (site of contact, site of metabolism and peripheral distribution) to be assessed for DNA damage. This combination approach was performed with minimal changes to the standard and regulatory recommended sampling times for the stand-alone assays. A series of eight in vivo genotoxins (2-acetylaminofluorene, benzo[a]pyrene, carbendazim, cyclophosphamide, dimethylnitrosamine, ethyl methanesulfonate, ethyl nitrosourea and mitomycin C), which are known to act via different modes of action (direct- and indirect-acting clastogens, alkylating agents, gene mutagens, cross-linking and aneugenic compounds) were tested. Male rats were dosed at 0, 24 and 45 h, and bone marrow and peripheral blood (micronucleus endpoint), liver, whole blood and stomach (Comet endpoint) were sampled at three hours after the last dose. Comet and micronucleus responses were as expected based on available data for conventional (acute) stand-alone assays. All compounds were detected as genotoxic in at least one of the endpoints. The importance of evaluating both endpoints was highlighted by the uniquely positive responses for certain chemicals (benzo[a]pyrene and 2-acetylaminofluorene) with the Comet endpoint and certain other chemicals (carbendazim and mitomycin C) with the micronucleus endpoint. The data generated from these investigations demonstrate the suitability of the multi-endpoint design.
Asunto(s)
Ensayo Cometa , Daño del ADN , Determinación de Punto Final , Pruebas de Micronúcleos/métodos , Mutágenos/toxicidad , Animales , Médula Ósea , Eritrocitos , Citometría de Flujo , Hígado/irrigación sanguínea , Linfocitos , Masculino , Ratas , Reticulocitos , Estómago/irrigación sanguíneaRESUMEN
Input data aggregation affects crop model estimates at the regional level. Previous studies have focused on the impact of aggregating climate data used to compute crop yields. However, little is known about the combined data aggregation effect of climate (DAEc) and soil (DAEs) on irrigation water requirement (IWR) in cool-temperate and spatially heterogeneous environments. The aims of this study were to quantify DAEc and DAEs of model input data and their combined impacts for simulated irrigated and rainfed yield and IWR. The Agricultural Production Systems sIMulator Next Generation model was applied for the period 1998-2017 across areas suitable for potato (Solanum tuberosum L.) in Tasmania, Australia, using data at 5, 15, 25 and 40 km resolution. Spatial variances of inputs and outputs were evaluated by the relative absolute difference (rAD¯) between the aggregated grids and the 5 km grids. Climate data aggregation resulted in a rAD¯ of 0.7-12.1%, with high values especially for areas with pronounced differences in elevation. The rAD¯ of soil data was higher (5.6-26.3%) than rAD¯ of climate data and was mainly affected by aggregation of organic carbon and maximum plant available water capacity (i.e. the difference between field capacity and wilting point in the effective root zone). For yield estimates, the difference among resolutions (5 km vs. 40 km) was more pronounced for rainfed (rAD¯ = 14.5%) than irrigated conditions (rAD¯ = 3.0%). The rAD¯ of IWR was 15.7% when using input data at 40 km resolution. Therefore, reliable simulations of rainfed yield require a higher spatial resolution than simulation of irrigated yields. This needs to be considered when conducting regional modelling studies across Tasmania. This study also highlights the need to separately quantify the impact of input data aggregation on model outputs to inform about data aggregation errors and identify those variables that explain these errors.
Asunto(s)
Suelo , Solanum tuberosum , Riego Agrícola , Australia , Cambio Climático , Agregación de Datos , Tasmania , AguaRESUMEN
Use of three-dimensional (3D) tissue equivalents in toxicology has been increasing over the last decade as novel preclinical test systems and as alternatives to animal testing. In the area of genetic toxicology, progress has been made with establishing robust protocols for skin, airway (lung) and liver tissue equivalents. In light of these advancements, a "Use of 3D Tissues in Genotoxicity Testing" working group (WG) met at the 7th IWGT meeting in Tokyo in November 2017 to discuss progress with these models and how they may fit into a genotoxicity testing strategy. The workshop demonstrated that skin models have reached an advanced state of validation following over 10 years of development, while liver and airway model-based genotoxicity assays show promise but are at an early stage of development. Further effort in liver and airway model-based assays is needed to address the lack of coverage of the three main endpoints of genotoxicity (mutagenicity, clastogenicity and aneugenicity), and information on metabolic competence. The IWGT WG believes that the 3D skin comet and micronucleus assays are now sufficiently validated to undergo an independent peer review of the validation study, followed by development of individual OECD Test Guidelines.
Asunto(s)
Daño del ADN/efectos de los fármacos , Metagenómica/tendencias , Pruebas de Mutagenicidad/métodos , Mutágenos/toxicidad , Daño del ADN/genética , Humanos , Hígado/efectos de los fármacos , Hígado/patología , Pruebas de MicronúcleosRESUMEN
The Mouse Lymphoma Assay (MLA) Workgroup of the International Workshop on Genotoxicity Testing (IWGT), comprised of experts from Japan, Europe and the United States, met on September 9, 2005, in San Francisco, CA, USA. This meeting of the MLA Workgroup was devoted to reaching a consensus on issues involved with 24-h treatment. Recommendations were made concerning the acceptable values for the negative/solvent control (mutant frequency, cloning efficiency and suspension growth) and the criteria to define an acceptable positive control response. Consensus was also reached concerning the use of the global evaluation factor (GEF) and appropriate statistical trend analysis to define positive and negative responses for the 24-h treatment. The Workgroup agreed to continue their support of the International Committee on Harmonization (ICH) recommendation that the MLA assay should include a 24-h treatment (without S-9) in those situations where the short treatment (3-4 h) gives negative results.
Asunto(s)
Linfoma/genética , Pruebas de Mutagenicidad/métodos , Mutación , Timidina Quinasa/genética , Animales , Ratones , Mutágenos/toxicidad , Factores de TiempoRESUMEN
Simulations are used to generate plausible realisations of soil and climatic variables for input into an enterprise land suitability assessment (LSA). Subsequently we present a case study demonstrating a LSA (for hazelnuts) which takes into account the quantified uncertainties of the biophysical model input variables. This study is carried out in the Meander Valley Irrigation District, Tasmania, Australia. It is found that when comparing to a LSA that assumes inputs to be error free, there is a significant difference in the assessment of suitability. Using an approach that assumes inputs to be error free, 56% of the study area was predicted to be suitable for hazelnuts. Using the simulation approach it is revealed that there is considerable uncertainty about the 'error free' assessment, where a prediction of 'unsuitable' was made 66% of the time (on average) at each grid cell of the study area. The cause of this difference is that digital soil mapping of both soil pH and conductivity have a high quantified uncertainty in this study area. Despite differences between the comparative methods, taking account of the prediction uncertainties provide a realistic appraisal of enterprise suitability. It is advantageous also because suitability assessments are provided as continuous variables as opposed to discrete classifications. We would recommend for other studies that consider similar FAO (Food and Agriculture Organisation of the United Nations) land evaluation framework type suitability assessments, that parameter membership functions (as opposed to discrete threshold cutoffs) together with the simulation approach are used in concert.
RESUMEN
The mouse lymphoma TK assay (MLA) is part of an in vitro battery of tests designed to predict risk assessment prior to in vivo testing. The test has the potential to detect mutagenic and clastogenic events at the thymidine kinase (tk) locus of L5178Y mouse lymphoma tk ( +/- ) cells by measuring resistance to the lethal nucleoside analogue triflurothymidine (TFT). Cells may be plated for viability and mutation in semi-solid agar (agar assay) or in 96-well microtitre plates (microwell assay). When added to selective medium containing TFT, wild-type tk ( +/- ) cells die, but TFT cannot be incorporated into the DNA of mutant tk ( -/- ) cells, which survive to form colonies that may be large (indicative of gene mutation) or small (indicative of chromosomal mutation) in nature. Mutant frequency is expressed as the number of mutants per 10(6) viable cells.